Read by QxMD icon Read

schizophrenia and smoking cessation

Emily Peckham, Catherine Arundel, Della Bailey, Stuart Brownings, Caroline Fairhurst, Paul Heron, Jinshuo Li, Steve Parrott, Simon Gilbody
BACKGROUND: Smoking is highly prevalent among people who have experience of severe mental ill health, contributing to their poor physical health. Despite the 'culture' of smoking in mental health services, people with severe mental ill health often express a desire to quit smoking; however, the services currently available to aid quitting are those which are widely available to the general population and may not be suitable or effective for people with severe mental ill health. The aim of this study is to explore the effectiveness and cost-effectiveness of a bespoke smoking-cessation intervention specifically targeted at people with severe mental ill health...
January 26, 2017: Trials
I-Hsuan Wu, Hua Chen, Patrick Bordnick, Ekere James Essien, Michael Johnson, Ronald J Peters, Xin Wang, Susan M Abughosh
BACKGROUND: Smoking cessation may lead to depression in some smokers and result in increased risk of suicide. OBJECTIVE: To compare the risk of suicide attempts/behaviors associated with different smoking cessation medications among schizophrenic patients. METHODS: A retrospective cohort study was conducted using General Electric (GE) medical record database (1995-2011). The first day of being prescribed a smoking cessation medication defined as index date...
February 2017: Archives of Psychiatric Nursing
Jane B Acri, Alan J Cross, Phil Skolnick
OBJECTIVE: This paper provides an overview of the role of type 2 metabotropic glutamate receptors (mGluR2) in addiction and behaviors reflecting addictive processes. RESULTS: AZD8529, an mGluR2 positive allosteric modulator (PAM), failed to separate from placebo in a phase II schizophrenia trial. The demonstration by Athina Markou's laboratory that AZD8529 attenuated both nicotine self-administration and cue-induced reinstatement was a key factor in the decision to move this compound into a smoking cessation study...
December 20, 2016: Psychopharmacology
María Paz García-Portilla, Julio Bobes
No abstract text is available yet for this article.
October 2016: Revista de Psiquiatrí́a y Salud Mental
Brian J Miller, Alexandre Wang, Joyce Wong, Nina Paletta, Peter F Buckley
BACKGROUND: Smoking is highly prevalent in patients with schizophrenia. Electronic cigarettes (e-cigarettes) are becoming increasingly popular among smokers. Surveys indicate overall favorable attitudes toward the use of e-cigarettes to reduce or quit smoking, relieve withdrawal symptoms, and with respect to perceived health risks; however, less is known about their use in patients with schizophrenia. In the present study, we investigated the prevalence of and attitudes toward e-cigarettes in patients with schizophrenia...
February 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
Morgane Besson, Benoît Forget
Although smoking prevalence has declined in recent years, certain subpopulations continue to smoke at disproportionately high rates and show resistance to cessation treatments. Individuals showing cognitive and affective impairments, including emotional distress and deficits in attention, memory, and inhibitory control, particularly in the context of psychiatric conditions, such as attention-deficit hyperactivity disorder, schizophrenia, and mood disorders, are at higher risk for tobacco addiction. Nicotine has been shown to improve cognitive and emotional processing in some conditions, including during tobacco abstinence...
2016: Frontiers in Psychiatry
Arthur L Brody, Todd Zorick, Robert Hubert, Gerhard S Hellemann, Shabnam Balali, Sarah S Kawasaki, Lizette Y Garcia, Ryutaro Enoki, Paul Abraham, Paulina Young, Charles McCreary
INTRODUCTION: The majority of people with schizophrenia have a diagnosis of tobacco dependence during their lifetime. A major obstacle to reducing the burden of cigarette smoking in this population is that these smokers have lower quit rates when undergoing standard treatment compared to smokers with no mental illness. We sought to determine if combination extended treatment (COMB-EXT) and home visits (HV) would lead to improved outcomes in smokers with schizophrenia. METHODS: Thirty-four cigarette smokers with schizophrenia completed either COMB-EXT with HV, COMB-EXT without HV, or treatment as usual (TAU) (random assignment)...
January 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
Gary J Tedeschi, Sharon E Cummins, Christopher M Anderson, Robert M Anthenelli, Yue-Lin Zhuang, Shu-Hong Zhu
BACKGROUND: People with mental health conditions (MHC) smoke at high rates and many die prematurely from smoking-related illnesses. Smoking cessation programs, however, generally do not screen for MHC. This study examined the utility of MHC screening in a large tobacco quitline to determine whether self-reported MHC predicts service utilization and quitting behaviors. METHODS & FINDINGS: A brief set of question on MHC was embedded in the routine intake of a state quitline, and 125,261 smokers calling from June 2012 to September 2015 were asked the questions...
2016: PloS One
Stéphane Potvin, Ovidiu Lungu, Olivier Lipp, Pierre Lalonde, Vessela Zaharieva, Emmanuel Stip, Jean-Pierre Melun, Adrianna Mendrek
BACKGROUND: Highly prevalent in schizophrenia, tobacco smoking substantially increases the risk of cardiac-related death. Compared to the general population, tobacco smoking cessation rates are lower in schizophrenia. Unfortunately, the reasons for these low cessation rates remain poorly understood. Recently, it has been shown that tobacco cravings are increased in schizophrenia smokers compared to smokers with no comorbid psychiatric disorder. In view of these results, we sought to examine - for the first time - the neurophysiologic responses elicited by cigarette cues in schizophrenia smokers...
May 2016: Schizophrenia Research
Huiqiong Deng, Jia Wang, Xiangyang Zhang, Mengying Ma, Coreen Domingo, Hongqiang Sun, Thomas Kosten
BACKGROUND AND OBJECTIVES: Tobacco use is a significant public health issue on a global scale. Prevalence of daily tobacco smoking for men in China is much higher than in the United States. Although prevailing literature suggests a negative relationship between smoking and quality of life, this pilot study sought to evaluate whether smoking reduction/cessation impacted on the perception of quality of life in an in-patient population in China. METHODS: Twenty Chinese patients meeting DSM-IV criteria for schizophrenia were recruited from Beijing Hui-Long-Guan Hospital, an in-patient facility in Beijing, China, for participation in this 4-week study...
March 2016: American Journal on Addictions
Priya Khanna, Andrew V Clifton, David Banks, Graeme E Tosh
BACKGROUND: People with a serious mental illness are more likely to smoke more and to be more dependent smokers than the general population. This may be due to a wide range of factors that could include a common aetiology to both smoking and the illness, self medication, smoking to alleviate adverse effects of medications, boredom in the existing environment, or a combination of these factors. It is important to undertake this review to facilitate improvements in both the health and safety of people with serious mental illness who smoke, and to reduce the overall burden of costs (both financial and health) to the smoker and, eventually, to the taxpayer...
2016: Cochrane Database of Systematic Reviews
Vinay Parikh, Munir Gunes Kutlu, Thomas J Gould
INTRODUCTION: The prevalence of tobacco use in the population with schizophrenia is enormously high. Moreover, nicotine dependence is found to be associated with symptom severity and poor outcome in patients with schizophrenia. The neurobiological mechanisms that explain schizophrenia-nicotine dependence comorbidity are not known. This study systematically reviews the evidence highlighting the contribution of nicotinic acetylcholine receptors (nAChRs) to nicotine abuse in schizophrenia...
March 2016: Schizophrenia Research
Alvin V Terry, Marc Plagenhoef, Patrick M Callahan
RATIONALE: Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing). OBJECTIVES: The purpose of this work was to evaluate in animals the smoking cessation agent, varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic acetylcholine receptors, for its potential as a repurposed drug for disorders of cognition...
March 2016: Psychopharmacology
Faith Dickerson, Andrea Origoni, Jennifer Schroeder, Lucy A B Schweinfurth, Cassie Stallings, Christina L G Savage, Emily Katsafanas, Maria Banis, Sunil Khushalani, Robert Yolken
Persons with schizophrenia and with bipolar disorder have a reduced life expectancy due largely to death from natural causes. The reasons for this increased mortality have not been completely defined. We prospectively assessed a cohort of persons with schizophrenia and one with bipolar disorder with a clinical evaluation and a blood sample from which immune and infectious disease markers were measured. Mortality was determined with data from the National Death Index following a period of up to 14years. We examined the role of demographic, clinical, and serological factors on mortality in bivariate and multivariate models...
January 2016: Schizophrenia Research
Emmert Roberts, A Eden Evins, Ann McNeill, Debbie Robson
BACKGROUND AND AIMS: To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. METHOD: We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials from database inception to 1 December 2014 for randomized controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking...
April 2016: Addiction
A Eden Evins, Corinne Cather
Despite availability of smoking cessation aids with proven efficacy and tolerability in those with schizophrenia, addiction to tobacco-derived nicotine remains highly prevalent among those with schizophrenia spectrum disorders. While smokers with serious mental illness have been excluded from most large nicotine-dependence treatment studies, and these treatments are woefully underutilized for smokers with psychiatric illness, a growing evidence base is available to guide cessation treatment for smokers with schizophrenia...
2015: International Review of Neurobiology
Simon Gilbody, Emily Peckham, Mei-See Man, Natasha Mitchell, Jinshuo Li, Taeko Becque, Catherine Hewitt, Sarah Knowles, Tim Bradshaw, Claire Planner, Steve Parrott, Susan Michie, Charles Shepherd
BACKGROUND: People with severe mental ill health are three times more likely to smoke but typically do not access conventional smoking cessation services, contributing to widening health inequalities and reduced life expectancy. We aimed to pilot an intervention targeted at smokers with severe mental ill health and to test methods of recruitment, randomisation, and follow up before implementing a full trial. METHODS: The Smoking Cessation Intervention for Severe Mental Ill Health Trial (SCIMITAR) is a pilot randomised controlled trial of a smoking cessation strategy designed specifically for people with severe mental ill health, to be delivered by mental health nurses and consisting of behavioural support and drugs, compared with a conventional smoking cessation service (ie, usual care)...
May 2015: Lancet Psychiatry
Bo-Jian Wu, Tsuo-Hung Lan
Many studies have investigated whether a type of antipsychotics or type of adjuvant is associated with smoking reduction in patients with schizophrenia. However, there has been no study exploring a comprehensive range of factors related to smoking reduction in schizophrenia patients. We analyzed a dataset of 287 smoking patients with schizophrenia who participated in an 8-week open-label study with high- (n = 90) or low-dose nicotine dermal patches (n = 132) or bupropion (n = 65). A logistic regression model and a linear mixed model were used to explore factors associated with the outcomes of smoking cessation and reduction, i...
February 2017: European Archives of Psychiatry and Clinical Neuroscience
Rahil Sanatinia, Sophie M Middleton, Tint Lin, Oliver Dale, Mike J Crawford
OBJECTIVE: To investigate the assessment and treatment of physical health in patients with personality disorder and compare this to the care received in schizophrenia. METHOD: We collected data from a random sample of 246 patients with personality disorder on monitoring and intervention for seven key aspects of physical health. We compared the results with those from a random sample with schizophrenia. RESULTS: In our sample, 160 (65%) people had the diagnosis of emotionally unstable personality disorder...
November 2015: Personality and Mental Health
James G Jackson, Francisco J Diaz, Lucelly Lopez, Jose de Leon
OBJECTIVES: Worldwide studies were combined to examine two hypotheses: (i) bipolar disorder is associated with smoking behaviors, compared with the general population; and (ii) smoking behavior prevalences in bipolar disorder are intermediate between those in major depressive disorder and those in schizophrenia. METHODS: Combined analyses used 56 articles on adults obtained from a PubMed search or the senior author's article collection. Odds ratios (ORs) and their 95% confidence intervals (CIs) compared current smoking, heavy smoking among current smokers, smoking cessation in ever smokers, and ever smoking in bipolar disorder versus control groups...
September 2015: Bipolar Disorders
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"